METTL3 May Regulate Testicular Germ Cell Tumors Through EMT and Immune Pathways

Yang Luo1,2,3,4, Yuan Sun1,2,3,4, Lei Li1,2,3,4

  • 1Center for Reproductive Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Cell Transplantation
|August 5, 2020
PubMed

Insights

METTL3 expression is reduced in testicular germ cell tumors (TGCTs), impacting patient survival. Upregulating METTL3 enhances tumor cell invasion and migration, suggesting its role as a prognostic marker and potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Testicular germ cell tumors (TGCTs) are prevalent in young men, with unclear development mechanisms and limited effective treatments.
  • Research into molecular mechanisms and therapeutic targets for TGCT is crucial for improving patient outcomes.
  • The role of METTL3, a key methylase involved in various cancers, in TGCT progression remains largely unelucidated.

Purpose of the Study:

  • To investigate the role of METTL3 in the occurrence and development of TGCT.
  • To determine if METTL3 can serve as a prognostic marker for TGCT patients.
  • To explore the impact of METTL3 on TGCT cell behavior and the tumor immune microenvironment.

Main Methods:

  • Analysis of METTL3 expression levels in TGCT tissues.
  • Overexpression of METTL3 in TGCT cells to assess functional changes.
  • Evaluation of cell proliferation, invasion, and migration.
  • Assessment of epithelial-mesenchymal transition (EMT)-related protein expression.
  • Correlation analysis between METTL3 expression and immune cell infiltration (CD8+ T cells, CD4+ T cells, NK cells).

Main Results:

  • METTL3 expression was significantly downregulated in TGCT tissues.
  • Low METTL3 expression correlated with poorer overall survival and relapse-free survival rates.
  • METTL3 overexpression increased TGCT cell proliferation, invasion, and migration, affecting EMT-related proteins.
  • METTL3 expression positively correlated with CD8+ T cell, CD4+ T cell, and natural killer cell infiltration.

Conclusions:

  • METTL3 functions as an independent prognostic marker for TGCT patients.
  • METTL3 influences TGCT cell proliferation, migration, and invasion via regulation of EMT-related genes.
  • METTL3 may play a role in modulating the tumor immune response within the TGCT microenvironment.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K